Back to top
more

GSK PLC Sponsored ADR (GSK)

(Delayed Data from NYSE)

$38.96 USD

38.96
4,990,122

-0.25 (-0.64%)

Updated Oct 17, 2024 04:00 PM ET

After-Market: $38.98 +0.02 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Gilead (GILD) Outpaces Industry in Six Months: What Lies Ahead?

Gilead (GILD) gains on the back of its strong HIV franchise and promising oncology business, which should propel growth further.

Pfizer (PFE) RSV Vaccine Found Effective in Older Adults

Based on the positive data from the phase III study on its RSV vaccine candidate, Pfizer plans to file a biologics license application (BLA) to the FDA in fall 2022.

Gilead (GILD) Twice-Yearly HIV Treatment Gets EC Approval

Gilead (GILD) HIV treatment Sunlenca gets approved by the European Commission for adults with multi-drug resistant HIV infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen.

Is Hartford Multifactor Developed Markets exUS ETF (RODM) a Strong ETF Right Now?

Smart Beta ETF report for RODM

Kinjel Shah headshot

Pharma Stock Roundup: End of SNY's Amcenestrant Development, FDA Updates for AZN, GSK

Sanofi (SNY) ends the development of breast cancer candidate, amcenestrant. Novartis' (NVS) lung cancer candidate, canakinumab fails a phase III study. FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) Lynparza sNDA.

GSK NDA for Myelofibrosis Candidate Gets FDA Acceptance

GSK's NDA for momelotinib for treating myelofibrosis was based on data from key phase III studies, including the pivotal MOMENTUM study.

Gilead (GILD) Announces Positive Data on Breast Cancer Drug

Gilead (GILD) breast cancer drug Trodelvy improves overall survival in pre-treated HR+/HER2- metastatic breast cancer patients. The company will also acquire the remaining rights to the drug.

PFE, GSK & Other Pharma Stocks Hit by Zantac Litigation

Big pharma stocks, such as Glaxo (GSK), Sanofi (SNY), Pfizer (PFE) and Consumer stock Haleon (HLN), decline due to the litigation surrounding the heartburn drug Zantac (ranitidine).

The Zacks Analyst Blog Highlights Amgen, ChemoCentryx, Mersana Therapeutics, GSK and Vertex Pharmaceuticals

Amgen, ChemoCentryx, Mersana Therapeutics, GSK and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.

Biotech Stock Roundup: AMGN's Q2 Earnings, CCXI Acquisition & More Updates

Earnings updates from Amgen (AMGN) and its ChemoCentryx (CCXI) acquisition are a few key highlights from the biotech sector during the past week.

Theravance's (TBPH) Q2 Earnings Beat, Focus on Pipeline

Theravance (TBPH) reports narrower-than-expected loss in the second quarter of 2022. Revenues improve year over year due to Viatris collaboration.

Gilead (GILD) Q2 Earnings & Sales Top, Revenue Outlook Upped

Gilead (GILD) reports better-than-expected second quarter results on strong HIV business. The company also raises its annual revenue guidance.

Is Nuveen ESG International Developed Markets Equity ETF (NUDM) a Strong ETF Right Now?

Smart Beta ETF report for NUDM

The Zacks Analyst Blog Highlights GSK, Merck, Pfizer, Sanofi and AstraZeneca

GSK, Merck, Pfizer, Sanofi and AstraZeneca are part of Zacks top Analyst Blog.

Kinjel Shah headshot

Pharma Stock Roundup: MRK, PFE, SNY Q2 Earnings & Sales Beat, GSK Results Mixed

GSK plc (GSK), Merck (MRK), Pfizer (PFE), Sanofi (SNY) and AstraZeneca (AZN) announce second-quarter results

GSK's Q2 Earnings Beat, Sales Miss, Raises 2022 Guidance

GSK's (GSK) revenues benefit from the strong growth in sales across all segments. The company raises its financial guidance for its Vaccines segment on the back of strong shingles vaccine sales.

Drug, Biotech Stocks' Q2 Earnings on Jul 27: BMY, GSK & More

Let's look what is in store for the four drug, biotech companies slated to release quarterly results tomorrow- BMY, GSK, ALKS, TEVA

GSK Gears Up to Report Q2 Earnings: What's in the Cards?

The newer respiratory and HIV drugs of GSK are likely to have driven second-quarter sales. The performance of Xevudy, GSK's monoclonal antibody for COVID-19, remains to be seen when the company reports.

The Zacks Analyst Blog Highlights J&J, Novartis, GSK, Merck and AbbVie

J&J, Novartis, GSK, Merck and AbbVie are included in this Analyst Blog.

GlaxoSmithKline (GSK) Gains As Market Dips: What You Should Know

GlaxoSmithKline (GSK) closed at $42.29 in the latest trading session, marking a +0.09% move from the prior day.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ, NVS Q2 Earnings, GSK Consumer Unit Spin-Off

J&J (JNJ) and Novartis (NVS) report Q2 earnings. GSK completes separation of its Consumer Healthcare (CHC) segment.

Tilray (TLRY) to Report Q4 Earnings: What's in the Cards?

Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports fiscal fourth-quarter results.

GSK Completes Demerger of Consumer Healthcare Business

Post demerger, GSK is set to focus on its Pharmaceuticals and Vaccines businesses. The consumer healthcare business, Haleon, will start regular-way trading on the NYSE from Jul 22.

The Zacks Analyst Blog Highlights Apple, UnitedHealth Group, Equinor, GSK and Eaton

Apple, UnitedHealth Group, Equinor, GSK and Eaton have been included in this Analyst Blog.

Sheraz Mian headshot

Top Analyst Reports for Apple, UnitedHealth, Equinor & Others

Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), UnitedHealth Group Incorporated (UNH), and Equinor ASA (EQNR).